91 related articles for article (PubMed ID: 30562867)
61. Stabilization of acute myeloid leukemia with a dendritic cell vaccine.
Massumoto C; Sousa-Canavez JM; Leite KR; Camara-Lopes LH
Hematol Oncol Stem Cell Ther; 2008; 1(4):239-40. PubMed ID: 20058480
[No Abstract] [Full Text] [Related]
62. Tax-Free Benefactions.
Hospital (Lond 1886); 1920 Jul; 68(1779):386. PubMed ID: 29829789
[No Abstract] [Full Text] [Related]
63. [HTLV-1-targeted immunotherapy].
Suehiro Y
Rinsho Ketsueki; 2016; 57(10):2250-2258. PubMed ID: 27795537
[TBL] [Abstract][Full Text] [Related]
64. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study.
Suehiro Y; Hasegawa A; Iino T; Sasada A; Watanabe N; Matsuoka M; Takamori A; Tanosaki R; Utsunomiya A; Choi I; Fukuda T; Miura O; Takaishi S; Teshima T; Akashi K; Kannagi M; Uike N; Okamura J
Br J Haematol; 2015 May; 169(3):356-67. PubMed ID: 25612920
[TBL] [Abstract][Full Text] [Related]
65. Short-term cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Tax-specific CTL response in adult T-cell leukemia patients.
Ishizawa M; Ganbaatar U; Hasegawa A; Takatsuka N; Kondo N; Yoneda T; Katagiri K; Masuda T; Utsunomiya A; Kannagi M
Cancer Sci; 2021 Mar; 112(3):1161-1172. PubMed ID: 33410215
[TBL] [Abstract][Full Text] [Related]
66. Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2RĪ³null mouse model.
Masaki A; Ishida T; Suzuki S; Ito A; Mori F; Sato F; Narita T; Yamada T; Ri M; Kusumoto S; Komatsu H; Tanaka Y; Niimi A; Inagaki H; Iida S; Ueda R
J Immunol; 2013 Jul; 191(1):135-44. PubMed ID: 23733874
[TBL] [Abstract][Full Text] [Related]
67. [Tax-targeted DC vaccine for ATL].
Suehiro Y
Nihon Rinsho; 2017 Feb; 75(2):295-300. PubMed ID: 30562867
[TBL] [Abstract][Full Text] [Related]
68. Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: A hope for disease-preventive therapy.
Kannagi M; Hasegawa A; Nagano Y; Iino T; Okamura J; Suehiro Y
Cancer Sci; 2019 Mar; 110(3):849-857. PubMed ID: 30666755
[TBL] [Abstract][Full Text] [Related]
69. [New treatment strategy for adult T-cell leukemia targeting for anti-tumor immunity and a longevity gene-encoded protein].
Kozako T
Yakugaku Zasshi; 2011; 131(7):1061-72. PubMed ID: 21720136
[TBL] [Abstract][Full Text] [Related]
70. Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia.
Kannagi M
Int J Hematol; 2007 Aug; 86(2):113-7. PubMed ID: 17875523
[TBL] [Abstract][Full Text] [Related]
71. Adult T-cell leukemia: future prophylaxis and immunotherapy.
Kannagi M; Harashima N; Kurihara K; Utsunomiya A; Tanosaki R; Masuda M
Expert Rev Anticancer Ther; 2004 Jun; 4(3):369-76. PubMed ID: 15161436
[TBL] [Abstract][Full Text] [Related]
72. Immunological risks of adult T-cell leukemia at primary HTLV-I infection.
Kannagi M; Ohashi T; Harashima N; Hanabuchi S; Hasegawa A
Trends Microbiol; 2004 Jul; 12(7):346-52. PubMed ID: 15223062
[TBL] [Abstract][Full Text] [Related]
73.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
74.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
